



## VISABL-AFL TRIAL FOR US FDA APPROVAL RECEIVES ETHICS APPROVAL AT CARDIOVASCULAR INSTITUTE OF SOUTH PARIS

### Highlights:

- The Ethics Committee at the Cardiovascular Institute of South Paris (ICPS) has approved VISABL-AFL clinical trial
- This is the first of two approvals required for ICPS to join the trial. The final approval required is from the French National Agency for Medicines and Health Products (ANSM), the Competent Authority in France.
- VISABL-AFL is the global trial to support US FDA approval of Imricor's products
- ICPS is expected to join Johns Hopkins and Lausanne University Hospital as third site to participate in the trial, with Amsterdam UMC to follow

**11 March 2024** – Melbourne, Australia (**10 March 2024** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR)** is pleased to announce that the Ethics Committee at the Cardiovascular Institute of South Paris (ICPS) has approved the VISABL-AFL clinical trial to commence at the site. This is the first of two approvals required for ICPS to join the trial. The second and last approval required is from the French National Agency for Medicines and Health Products (ANSM), the Competent Authority in France.

VISABL-AFL is the global clinical trial to support FDA approval of Imricor's products in the United States.

ICPS (<https://icps.fr>) has constructed a new cardiology-owned MRI lab with design input from Imricor to ensure the lab is appropriately configured for interventions with Imricor's products.

Upon joining the trial, physicians at ICPS will join physicians at Johns Hopkins Hospital and the Lausanne University Hospital (CHUV) in enrolling patients suffering from atrial flutter into VISABL-AFL. The Ethics Committee approval process at Amsterdam UMC is also underway.

With four sites planning to participate in VISABL-AFL, the Company expects to complete the trial by year-end 2024.

**Imricor's Chair and CEO, Steve Wedan, commented:** "After last week's announcement regarding Ethics Committee approval at the CHUV in Lausanne, we are very excited to announce that the Ethics Committee at ICPS has followed so quickly.

"This is another big step forward for VISABL-AFL, and it reinforces the fact that our FDA approval process and ultimate US launch are on schedule."

### ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.



## Media and Investor Relations Contact:

Simon Hinsley  
simon@nwrcommunications.com.au  
+61 401 909 653

### About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out real-time iCMR cardiac ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac ablation procedures.

### Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union and the Kingdom of Saudi Arabia (KSA) with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also pursuing the required regulatory approvals to place its key products on the market in Australia, the U.S., and the other Middle East countries.

The Company has also obtained approval within the EU and KSA for the sale of the Advantage-MR EP Recorder/Stimulator System and other consumable products, such as the Vision-MR Diagnostic Catheter and Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V., Siemens Healthcare GmbH, and GE HealthCare help to target certain sites and support the design and construction of iCMR labs for those sites.

### Foreign Ownership Restrictions

Imricor's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.